title: Development of New Psychopharmacological Agents for Depression and Anxiety.
abstract: Antidepressant and anxiolytic drug development has largely stalled. This article reviews novel current programs for developing depressants and anxiolytics. Biological bases are discussed for these, as are recent results. Problems encountered are reviewed. Recently announced failed programs for other antidepressants are then discussed with an eye toward uncovering possible common elements that may explain their failures. Lastly, possible solutions for improving the likelihood of the success of antidepressant/anxiolytic agents are discussed.
authors: Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305-5797, USA. Electronic address: afschatz@stanford.edu.
authors: Alan F
authors: AF
authors: Schatzberg
mesh_terms: D014151:Anti-Anxiety Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy* / Q000523:psychology*; D001905:Botulinum Toxins / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy* / Q000523:psychology*; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D007649:Ketamine / Q000627:therapeutic use; D015735:Mifepristone / Q000627:therapeutic use; D058990:Molecular Targeted Therapy / Q000379:methods; D009435:Synaptic Transmission / Q000187:drug effects*
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D018691:Excitatory Amino Acid Antagonists; D006727:Hormone Antagonists; D015735:Mifepristone; D007649:Ketamine; D001905:Botulinum Toxins
keywords: Antidepressants; Anxiolytics; Glucocorticoid antagonists; Glutamatergic agents; Ketamine; Mu-opioid agents; NMDA antagonists; Obotulinum toxin